# Heron Therapeutics

Type: Company (HRTX)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/heron-therapeutics
Canonical HTML page: https://getfinancebrief.com/entity/heron-therapeutics

## Recent coverage (2 stories)

### Mid-Cap Biotech Resilience: Lantheus and Heron Navigate Mixed Q4 Results
2026-02-26 13:18:52 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.
Full story: https://getfinancebrief.com/story/lantheus-heron-q4-earnings-fy26-outlook

### Biotech Earnings Preview: Delcath, Butterfly, Heron, and Lantheus Set Q4 Outlook
2026-02-25 15:07:55 · Sentiment: Neutral · Impact: 5/10 · Sources: 4

As the Q4 2025 earnings season intensifies, four key players in the specialized medical technology and biotechnology sectors—Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings—are preparing to report results. Investors are focusing on commercial execution, product adoption rates, and the sustainability of high-growth specialized therapies.
Full story: https://getfinancebrief.com/story/biotech-medtech-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.